Miami, Florida, November 28, 2025 Pasithea Therapeutics has announced the pricing of a $60 million public offering ,strengthening its financial position and extending its operational runway through at least the first half of 2028 .The offering, led by major healthcare-focused institutional investors, will support the advancement of PAS-004, the company’s next-generation macrocyclic oral MEK inhibitor currently in Phase 1 clinical trials for cancers and neurofibromatosis type 1–associated plexiform neurofibromas (NF1-PN). The move strengthens Pasithea’s capacity to expand early-stage programs, progress clinical studies, and explore synergistic technology acquisitions.
Science Significance
The scientific importance of this announcement lies in the advancement of PAS-004, a promising macrocyclic MEK inhibitor designed to overcome limitations of earlier MAPK-pathway drugs. MEK inhibitors have long been central to therapeutic strategies targeting RASopathies and MAPK-driven tumors, but challenges remain in achieving sustained inhibition with improved safety. PAS-004’s development aims to address structural and pharmacokinetic limitations seen in earlier agents. With ongoing Phase 1 and Phase 1/1b trials evaluating the drug in advanced cancers and NF1-PN, additional funding enables deeper investigation into its pharmacokinetics, pharmacodynamics, and preliminary efficacy, supporting the broader scientific understanding of MEK-targeted therapies
Regulatory Significance
The offering proceeds will help the company advance programs aligned with regulatory milestones, including continued execution of FDA-registered Phase 1 clinical trials and future clinical-development steps required for PAS-004. As the company progresses through early-phase trials, data generated will shape future discussions with regulatory authorities regarding safety, tolerability, optimal dosing, and early signals of therapeutic benefit. Pasithea’s effective registration statement on Form S-1, declared effective on November 28, 2025, further underscores its compliance with public-market and disclosure regulations while enabling the offering to proceed within SEC guidelines. Strengthening its financial foundation positions the company to meet regulatory documentation, clinical-trial operational requirements, and future IND-related expansions
Business Significance
Advertisement
From a business perspective, the $60 million capital infusion is transformative. Led by a consortium of well-established institutional investors—Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management—the raise signals strong external confidence in Pasithea’s pipeline and strategic direction. The financing provides critical runway to support corporate expansion, clinical development, new technology licensing, potential acquisitions, and continued investment in emerging therapeutic platforms. By securing resources through 2028, Pasithea can focus strategically on R&D execution, market-expansion planning, and value creation without near-term liquidity constraints, strengthening its competitive position in the biotech market
Patients’ Significance
Patients with NF1-PN, RASopathies, and MAPK-driven tumors face significant unmet clinical need, with limited treatment options capable of managing tumor progression safely and effectively. PAS-004’s progression through early-phase trials provides hope for a new targeted therapy that may offer improved safety, specificity, and dosing convenience compared to existing MEK inhibitors. Sustained funding ensures that clinical studies continue without delay, facilitating the generation of evidence required to support future therapeutic availability. For patients with life-altering genetic and oncologic diseases, the financing represents a direct investment in continued scientific innovation aimed at expanding future treatment choices.
Policy Significance
This announcement also reflects broader policy-relevant trends in U.S. biotechnology financing and regulatory interaction. Pasithea’s ability to execute a large-scale public offering under an effective SEC registration highlights the functioning of policy frameworks designed to support early-stage biotech financing. Additionally, with therapeutic innovation for rare diseases being a national priority, continued investor support reinforces the alignment between public policy goals and private-sector development. The capital raised will help Pasithea navigate future regulatory pathways, meet clinical-trial compliance requirements, and maintain transparency expectations in alignment with federal oversight and biotechnology governance standards.
With a substantial $60 million public offering secured and an extended cash runway through 2028, Pasithea Therapeutics is poised to accelerate the development of PAS-004 and expand its innovation pipeline. The company’s strengthened financial foundation enhances its ability to execute clinical, regulatory, scientific, and strategic initiatives that support long-term growth. As Pasithea advances its mission to deliver targeted therapies in oncology and rare genetic disorders, the new funding marks a significant milestone in enabling future progress for patients and the broader biopharmaceutical landscape.
Source: Pasithea Therapeutics Corp. press release
